Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Pharmacy · PA · Neurology, Pharmacy, PediatricsMedium impact

08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)

Act
by Mar 23, 2026
Effective date
Mar 23, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross updated policy 08.01.36f to version 08.01.36i, effective 03/23/2026. Zolgensma eligibility expanded to include SMA Types 0-3, removing the previous requirement to document 2 or fewer SMN2 gene copies. Two ICD-10 diagnosis codes (G12.0 and G12.1) were removed from the policy. Experimental and investigational sections were revised for clarity with no intent changes.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Mar 23, 2026 · 5 steps
01Billing team must update claim submission logic to remove ICD-10 codes G12.0 and G12.1 from this policy's documentation requirements.
02Update prior authorization templates and coverage determination tools to reflect that Zolgensma (J3399) now covers SMA Types 0-3 without requiring SMN2 gene copy documentation.
03Providers prescribing Zolgensma should be notified that expanded eligibility eliminates the previous genetic testing requirement for SMN2 copies.
04Update billing software rules and claim edits accordingly.
05Claims submitted after the effective date with G12.0 or G12.1 as supporting diagnosis codes for this policy may be denied or require resubmission with appropriate SMA type documentation (Q87.89 or other applicable codes).

Codes mentioned

J2326J3399J3405G12.0G12.1

Original notice

08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
08.01.36i, Therapies for Spinal Muscular AtrophyHighEffective Sep 14, 2026 · Medical Policy08.01.36h, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)MediumEffective Jul 1, 2026 · PharmacyMA08.086d, Nusinersen (Spinraza®)LowEffective Jan 1, 2024 · PharmacyMA08.086d, Nusinersen (Spinraza®)LowNo effective date · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesPA policy changesNeurologyPharmacyPediatricsCode J2326Code J3399Code J3405Code G12.0Code G12.1

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account